PET scans may predict breast cancer drug response before surgery
NCT ID NCT01937117
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at the start and on day 15. The goal is to see if a drop in tumor activity on the scan correlates with no cancer remaining at surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab and pertuzumab
What this could lead to
If early PET changes reliably predict response, doctors could tailor treatment more quickly, avoiding ineffective therapy and its side effects.
What could go wrong
This is a small, early-phase study focused on imaging correlation, not treatment outcome. The approach may not prove accurate enough for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Fred Hutchinson Cancer Research Center - University of Washington
Seattle, Washington, 98109, United States
-
Indiana University Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287-0013, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, 35294, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States